Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment

Leukemia Research

Volumn 34, Issue 5, 2010, Pages

  Breccia, Massimo ^a   Muscaritoli, Maurizio ^a   Cannella, Laura ^a   Loglisci, Giuseppina ^a   Santopietro, Michelina ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; GLUCOSE; IMATINIB; OCTAMER TRANSCRIPTION FACTOR 1; PROTEIN C JUN; PROTEIN KINASE LYN;

CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; LETTER; MASS FRAGMENTOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RNA SYNTHESIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 77950089707     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.11.021     Document Type: Letter

References (7)

1. Quintas-Cardama A., Cortes J.E. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006, 81:973-988.
2. Apperley J.F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8:1018-1029.
3. Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006, 12:7374-7379.
4. Melo J.V., Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007, 249:121-132.
5. Kominsky D.J., Klawitter J., Brown J.L., Boros L.G., Melo J.V., Eckhardt S.G., et al. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL positive cells. Clin Cancer Res 2009, 15:3442-3450.
6. Breccia M., Alimena G. The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism. Leuk Res 2009, 33:871-875.
7. Van den Abbeele A.D., Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal tumours (GISTs). Eur J Cancer 2002, 38(Suppl. 5):S60-S65.